What does this research mean for the field?

Post-translational modifications (PTMs) govern critical immune states in cancer and provide a superior biomarker framework for predicting immunotherapy resistance, checkpoint competence, and tumor visibility compared to static expression markers. Novelty: ClaimNovelty.SYNTHESIS. Consensus alignment: ConsensusAlignment.NEUTRAL.

What question did this study set out to answer?

To establish a biomarker-oriented framework linking post-translational modifications to core immune constraints, including checkpoint competence, tumor visibility, and immunotherapy resistance.

August 23, 2026International Journal of OncologyOpen Access

Post‑translational modification‑governed immune states in cancer immunity: Biomarker implications for checkpoint competence, tumor visibility and immunotherapy resistance (Review)

View Full Paper

Ask AI

Bookmark

Authors

JPJinghao Pan BLBoyang Li RLRuonan Lin

Discussion

Member takes

Overview

Review outlines post-translational modification-driven immune states in cancer immunotherapy, highlighting dynamic protein-state biomarkers for patient stratification and combination therapy design.

Key Points

To establish a biomarker-oriented framework linking post-translational modifications to core immune constraints, including checkpoint competence, tumor visibility, and immunotherapy resistance.
Reviewed mechanistic and translational evidence across five exemplar post-translational modification axes: glycosylation, palmitoylation, ubiquitin editing, phosphorylation, and lactylation.
Assessed data integration strategies combining proteogenomics, immunopeptidomics, and spatial profiling for biomarker discovery and clinical validation.
Reframed programmed death-ligand 1 (PD-L1) and antigen-presentation machinery as dynamic protein-state variables rather than static abundance markers.
Linked stress-induced post-translational modifications, including lactylation and chromatin-coupled suppression, to metabolic immune dysfunction and therapeutic resistance.
Defined a phase-aware translational pathway using mechanism-proximal modification readouts for pretreatment patient stratification, pharmacodynamic monitoring, and rational combination therapy design.

Cite This Study

Pan et al. (2026) studied this question.

synapsesocial.com/papers/6a8aae007677a34114446a34 https://doi.org/10.3892/ijo.2026.5932

View Full Paper

Ask AI

Bookmark

August 23, 2026International Journal of OncologyOpen Access

Post‑translational modification‑governed immune states in cancer immunity: Biomarker implications for checkpoint competence, tumor visibility and immunotherapy resistance (Review)

View Full Paper

Ask AI

Bookmark

Authors

JPJinghao Pan BLBoyang Li RLRuonan Lin

Discussion

Member takes

Overview

Review outlines post-translational modification-driven immune states in cancer immunotherapy, highlighting dynamic protein-state biomarkers for patient stratification and combination therapy design.

Key Points

To establish a biomarker-oriented framework linking post-translational modifications to core immune constraints, including checkpoint competence, tumor visibility, and immunotherapy resistance.
Reviewed mechanistic and translational evidence across five exemplar post-translational modification axes: glycosylation, palmitoylation, ubiquitin editing, phosphorylation, and lactylation.
Assessed data integration strategies combining proteogenomics, immunopeptidomics, and spatial profiling for biomarker discovery and clinical validation.
Reframed programmed death-ligand 1 (PD-L1) and antigen-presentation machinery as dynamic protein-state variables rather than static abundance markers.
Linked stress-induced post-translational modifications, including lactylation and chromatin-coupled suppression, to metabolic immune dysfunction and therapeutic resistance.
Defined a phase-aware translational pathway using mechanism-proximal modification readouts for pretreatment patient stratification, pharmacodynamic monitoring, and rational combination therapy design.

Cite This Study

Pan et al. (2026) studied this question.

synapsesocial.com/papers/6a8aae007677a34114446a34 https://doi.org/10.3892/ijo.2026.5932

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark